Latest Content

Novo Nordisk is using its first Super Bowl commercial to spotlight an oral formulation of Wegovy that builds on prior approvals of semaglutide, signaling a strategy to expand obesity treatment access beyond injectable GLP-1s.

TrumpRx is meant to reduce drug costs, but Americans are wondering how it works and what impact it will have.

FDA Commissioner Marty Makary’s warning against mass-marketed copycat drugs escalated the regulatory and legal clash over compounded oral GLP-1 products.

What did industry experts and insiders tell Pharmaceutical Executive at the start of 2026?

The site offers users coupons for a limited number of medications that can be redeemed at pharmacies and/or manufacturer DTC sites.

In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical protocols should be treated as product launch blueprints, and Veradermics completes an upsized $256 million IPO.

By giving small and mid-size biotechs access to real-world data and advanced analytics once reserved for large pharma, AI platforms are leveling the playing field by enabling lean teams to de-risk clinical strategy, strengthen fundraising narratives, and make faster, more confident decisions across the development lifecycle.

The approval is for a new formulation of the medication that allows for it be provided as an oral film.

Veradermics’ above-range IPO highlights renewed investor selectivity in biotech, favoring late-stage companies with clear clinical milestones and exposure to large, consumer-driven markets.

Novo Nordisk posted strong 2025 sales growth driven by obesity treatments and U.S. market performance, but tempered operating profits signal a more cautious outlook for 2026.

Novartis reported solid full-year growth and margin expansion in 2025, but also set the stage for a challenging year ahead marked by major patent expirations.

The outlook highlights major progress in reducing U.S. breast cancer deaths through improved screening and treatment, while noting that rising incidence and ongoing disparities continue to challenge patients and the health care system.

In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application for a subcutaneous indication of Saphnelo, and SanegeneBio enters a $1 billion global licensing agreement with Genentech focused on RNAi development.